Welcome to our dedicated page for Mindset Pharma news (Ticker: MSSTF), a resource for investors and traders seeking the latest updates and insights on Mindset Pharma stock.
Mindset Pharma Inc. (MSSTF) is a pioneering drug discovery company developing novel psychedelic-based therapies for neurological and psychiatric disorders. This news hub provides investors and industry professionals with timely updates on corporate developments, research breakthroughs, and strategic partnerships shaping the future of neuropsychiatric treatments.
Track official announcements including acquisition updates, clinical progress, and intellectual property milestones. The recent definitive arrangement with Otsuka Pharmaceutical demonstrates Mindset's position in advancing next-generation medications, with shareholders benefiting from premium valuation through this strategic transaction.
Discover updates across key categories: partnership developments, therapeutic research advancements, regulatory progress, and intellectual property expansion. Bookmark this page for direct access to verified information about Mindset's innovative compounds and their potential to address critical unmet medical needs.
Mindset Pharma Inc. (CSE: MSET, OTCQB: MSSTF) announced the filing of two international patent applications under the Patent Cooperation Treaty (PCT) for its non-hallucinogenic novel non-tryptamine compounds, known as "Family 6." These applications are based on promising pre-clinical studies, which indicate potential for treating a broader patient population, including vulnerable groups such as children and the elderly. The CEO, James Lanthier, emphasized that these compounds activate the 5-HT2A serotonin receptor without eliciting hallucinogenic effects, thereby reducing treatment costs and improving accessibility. This strategic move aims to position Mindset favorably in the psychedelic medicine market, focusing on innovative treatments for neuropsychiatric and neurological disorders.
Mindset Pharma Inc. (OTCQB: MSSTF) will participate in the Sequire Cannabis & Psychedelics Conference on April 5, 2023. CEO James Lanthier is scheduled to present at 1:30 p.m. ET. The event will be held virtually, and registration is available online. Mindset Pharma focuses on developing novel, optimized psychedelic and non-psychedelic medications aimed at treating neuropsychiatric and neurological disorders. The company has partnerships for its innovative compounds and aims to leverage the therapeutic potential of psychedelics for unmet medical needs. For further details, stakeholders can contact Mindset's strategic communications team.
Mindset Pharma (OTCQB: MSSTF) has announced significant advancements in 2022, emphasizing its commitment to developing innovative neuropsychiatric medications. The company is set to initiate human trials for MSP-1014, a prodrug of psilocin, which may offer improved safety and tolerability compared to traditional psilocybin. Mindset is also collaborating with the McQuade Center for Strategic Research and Development to advance its Family 2 compounds with higher potency and shorter effects than psilocybin. Additionally, the firm is exploring non-hallucinogenic drug candidates, aiming to expand therapeutic applicability across various patient populations.
